TY - JOUR T1 - ▼Acarbose for non-insulin-dependent diabetes mellitus JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 51 LP - 53 DO - 10.1136/dtb.1994.32751 VL - 32 IS - 7 A2 - , Y1 - 1994/07/01 UR - http://dtb.bmj.com/content/32/7/51.abstract N2 - Relevant BNF section: 6.1.2.3Acarbose (Glucobay - Bayer) is the first in a new class of oral antidiabetic drugs, the α-glucosidase inhibitors. It is licensed for the treatment of patients with non-insulin-dependent diabetes mellitus (NIDDM), either as first-line therapy when dietary measures are insufficient, or as an adjunct to conventional oral therapy where glycaemic control is suboptimal. The manufacturer claims that acarbose "can achieve a new level of blood glucose control in diabetes". In this article we consider whether acarbose offers any real advance. ER -